Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?

Area of Science:

• Cardiology
• Pharmacology
• Drug Development

Background:

• Coronary artery disease (CAD) is a leading global cause of mortality.
• Anticoagulants are crucial for preventing CAD progression to myocardial infarction and death.
• Direct Factor Xa (FXa) inhibitors represent a class of anticoagulants under investigation for CAD treatment.

Purpose of the Study:

• To review the development and clinical evidence of direct FXa inhibitors for CAD, particularly in acute coronary syndromes (ACS).
• To assess the current status and efficacy of FXa inhibitors like DX-9065a, otamixaban, apixaban, and rivaroxaban.

Main Methods:

• Review of preclinical and clinical trial data for direct FXa inhibitors in CAD and ACS.
• Analysis of Phase II and Phase III clinical trial outcomes comparing FXa inhibitors with standard anticoagulants or placebo.

Main Results:

• DX-9065a development halted due to lack of significant benefit over heparin in Phase II trials.
• Otamixaban showed potential benefit in some ACS trials but is not currently in further development.
• Apixaban and rivaroxaban have not demonstrated clear benefits in Phase II ACS trials but are progressing to Phase III.

Conclusions:

• Despite ongoing Phase III trials for apixaban and rivaroxaban in ACS, compelling evidence supporting the use of direct FXa inhibitors in this setting is currently lacking.
• Further research and robust clinical data are needed to establish the role of direct FXa inhibitors in managing ACS.